



January 19, 2022

**BSE Limited**

Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001.**

✓ **National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051.**

**Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations  
and Disclosure Requirements) Regulations, 2015.**

**Dear Sir/Madam,**

Enclosed is a Press Release as regards the Company having entered into a first partnership with Shenzhen Foncoo Pharmaceutical Co. Ltd. which reinforces its commitment to bringing high quality generic and complex generic medicines to patients around the world.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

**FOR LUPIN LIMITED**

**R. V. SATAM  
COMPANY SECRETARY  
(ACS-1 1973)**

Encl- : a/a.

## **Lupin Signs First Partnership Agreement with Foncoo for China**

**Mumbai, Shanghai, January 19, 2022:** Global pharma major Lupin Limited (Lupin) today announced that it has entered into a partnership with Shenzhen Foncoo Pharmaceutical Co. Ltd (Foncoo). This is Lupin's first partnership arrangement in China and reinforces Lupin's commitment to bringing high quality generic and complex generic medicines to patients around the world.

**Dr. Fabrice Egros, President – Growth Markets, Lupin said,** "Lupin continues to invest in key growth markets. With China's growing commitment to affordable and accessible healthcare, Lupin is committed to serving the healthcare needs of the Chinese population by providing high quality generic and complex generic products. We are very excited about our partnership with Foncoo. We will continue exploring additional partnership opportunities in China to leverage our global portfolio including complex generics and specialty medicines."

**Mr. Peng Yan, General Manager, Foncoo said,** "Foncoo's successful experiences on importing registration and marketing of the generic formulations and Lupin's strong capability of making high-quality medicines make us perfect match to each other and our collaboration will have a bright future most likely. We expect that the successful launch of our first product in China will come smoothly and soon. We will also continue exploring more opportunities to work with Lupin for providing more and more high-valued and complex medicines to the Chinese physicians and patients."

### **About Lupin**

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 9.6% of its revenue in research and development in FY21.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit [www.lupin.com](http://www.lupin.com) for more information.

Follow us on Twitter: <https://twitter.com/LupinGlobal> | LinkedIn: <https://www.linkedin.com/company/lupin>

Facebook: <http://www.facebook.com/LupinWorld/>

### **About Shenzhen Foncoo Pharmaceutical Co., Ltd.**

Shenzhen Foncoo Pharmaceutical Co., Ltd. specializes in providing pharmaceutical products that treat Central Nervous System disorders. Its headquarter is located in Shenzhen, China. Shenzhen Foncoo is committed to

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

the cause of improving the physical and mental health of humans and strives to provide Chinese patients with premium-quality CNS medicines. The goal of Shenzhen Foncoo is to become the most respected mental healthcare leader in ten years.

Foncoo's medicine sales network covers more than 5,000 hospitals in 31 provinces across China, serving more than 5 million patients.

Foncoo have accumulated rich experiences and formed keen market insights on CNS medicines after focusing on the same area for many years. By utilizing global resources, Foncoo has successfully launched a number of psychiatric drugs in China and continues widening its product pipeline to innovative complex formulations and novel drugs.

Please visit [www.foncoo.com](http://www.foncoo.com) for more information.

**For further information or queries please contact –**

**Shweta Munjal**

Vice President & Head – Corporate Communications

Email: [shwetamunjal@lupin.com](mailto:shwetamunjal@lupin.com)